本页面由Tiger Trade Technology Pte. Ltd.提供服务

Cogent Biosciences, Inc.

30.67
-0.3300-1.06%
成交量:63.09万
成交额:1,932.43万
市值:53.22亿
市盈率:-14.20
高:31.02
开:30.81
低:30.24
收:31.00
52周最高:43.73
52周最低:13.78
股本:1.74亿
流通股本:1.67亿
量比:1.00
换手率:0.38%
股息:- -
股息率:- -
每股收益(TTM):-2.1600
每股收益(LYR):-2.5504
净资产收益率:-109.74%
总资产收益率:-43.84%
市净率:11.38
市盈率(LYR):-12.03

数据加载中...

2026/09/03

重要事件披露

Form 8-K - Current report
2026/08/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/14

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/08/10

重要事件披露

Form 8-K - Current report
2026/08/10

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/10

重要事件披露

Form 8-K - Current report
2026/07/31

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/07/28

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/06/12

重要事件披露

Form 8-K - Current report
2026/05/14

超过5%披露

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2026/05/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/05/05

重要事件披露

Form 8-K - Current report
2026/03/31

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/02/17

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2026/02/17

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2026/02/17

重要事件披露

Form 8-K - Current report
2026/01/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/12/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/12/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/12/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities